iBio receives Nasdaq noncompliance notice over minimum bid price requirement
IBIO•iBio received a Nasdaq notice for failing to meet the $1 minimum closing bid requirement for 30 consecutive business days. It has until May 18, 2027, to regain compliance, and management may consider a reverse stock split if necessary.
1. Compliance period
iBio received a Nasdaq deficiency notice on November 19, 2026, after its common stock failed to meet the $1 minimum closing bid requirement for 30 consecutive business days. The notice has no immediate effect on trading, and the stock remains listed on the Nasdaq Capital Market under IBIO.
2. Steps to regain listing
The 180-day compliance period ends May 18, 2027. iBio must have a closing bid of at least $1 for at least 10 consecutive business days to regain compliance. A further 180-day extension depends on meeting Nasdaq eligibility requirements; otherwise, the stock faces delisting. Management may consider a reverse stock split if necessary to regain compliance and maintain the listing.




